Comparing CHA
Atrial fibrillation
CHA2DS2-VA
CHA2DS2-VASc
Risk prediction
Stroke
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
08
05
2024
revised:
01
06
2024
accepted:
03
06
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Contemporary data have shown a decrease in the ischaemic stroke risk associated with female sex in patients with atrial fibrillation (AF). We evaluated temporal trends in the predictive value of a non-sex CHA The FinACAF study covers all patients with incident AF between 2007 and 2018 in Finland from all levels of care. The CHA We identified 144,879 anticoagulant naïve patients with new-onset AF between 2007 and 2018 (49.9% women; mean age 72.1 years), of whom 3936 (2.7%) experienced ischaemic stroke during one-year follow-up. Based on both continuous and category-based NRIs, the CHA In 2007-2008 (when females had higher AF-related stroke risks than males), the CHA This work was supported by the Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, The Finnish State Research funding, and Helsinki and Uusimaa Hospital District research fund.
Sections du résumé
Background
UNASSIGNED
Contemporary data have shown a decrease in the ischaemic stroke risk associated with female sex in patients with atrial fibrillation (AF). We evaluated temporal trends in the predictive value of a non-sex CHA
Methods
UNASSIGNED
The FinACAF study covers all patients with incident AF between 2007 and 2018 in Finland from all levels of care. The CHA
Findings
UNASSIGNED
We identified 144,879 anticoagulant naïve patients with new-onset AF between 2007 and 2018 (49.9% women; mean age 72.1 years), of whom 3936 (2.7%) experienced ischaemic stroke during one-year follow-up. Based on both continuous and category-based NRIs, the CHA
Interpretation
UNASSIGNED
In 2007-2008 (when females had higher AF-related stroke risks than males), the CHA
Funding
UNASSIGNED
This work was supported by the Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, The Finnish State Research funding, and Helsinki and Uusimaa Hospital District research fund.
Identifiants
pubmed: 39171253
doi: 10.1016/j.lanepe.2024.100967
pii: S2666-7762(24)00134-0
pmc: PMC11337097
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100967Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
KT: Research Grants: The Finnish Foundation for Cardiovascular Research, Aarne and Aili Turunen Foundation and the Finnish State Research Funding GYHL: None. OH: none. JP: Speaker: Bayer, Boehringer-Ingelheim, BMS-Pfizer, Abbott; Advisory board: Portola, Novo Nordisk, Herantis Pharma; Visiting editor: Terve Media; Stock ownership: Vital Signum. PM: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. JHau: Consultant: Research Janssen R&D; Speaker: Bayer Finland. MLi: Speaker: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim. JHar: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. KEJA: Research grants: The Finnish Foundation for Cardiovascular Research; Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. MLe: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.